← Eichor
Condition: Lymphoblastic Lymphoma Lbl Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lymphoblastic Lymphoma Lbl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3 · 228 location(s) · University Hospital Muenster · NCT04043494Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-
Phase 1/Phase 2 · 163 location(s) · SWOG Cancer Research Network · NCT04315324U69-CART-Cells For R/R T-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07350863A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leuke
Phase 1/Phase 2 · 2 location(s) · University of Chicago · NCT06207123VHAG in Treating R/R T-ALL/LBL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06742463CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106749Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06909474To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07280494SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07153068Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
NA · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT05626400Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06874946CAYA Cancer Retrospective Cohort Study
Phase N/A · 5 location(s) · Resonance, Inc. · NCT07246213CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Phase 1 · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT06136364Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymp
Phase 3 · 2 location(s) · Children's Cancer Group, China · NCT05681260CAYA Cancer Prospective Cohort Study
Phase N/A · 3 location(s) · Resonance, Inc. · NCT07632014
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.